GlassScriptPhysician profile
Jaime Wilson
NPI 1538689542
$2,716.60
in general payments reported to CMS, 2019-2025
22 companies · $98.40 in 2025
The $98.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $867 · 2023: $805 · 2024: $107 · 2025: $98.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.96 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $825.71 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $367.71 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $202.35 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $174.20 | 2021-2022 | |
| Amgen INC. | $144.29 | 2021-2023 | Repatha |
| Novocure INC. | $128.74 | 2023 | Optune |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Abbvie INC. | $111.03 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.05 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $78.69 | 2021-2022 | |
| Pfizer INC. | $78.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $56.58 | 2021-2022 | |
| Inari Medical, INC. | $39.65 | 2022 | |
| Medtronic, INC. | $37.37 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.98 | 2021 | |
| Merck Sharp & Dohme LLC | $27.39 | 2021-2022 | |
| Irhythm Technologies, INC. | $26.68 | 2021 | |
| Abiomed | $19.40 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2022 | |
| Chiesi USA, INC. | $18.62 | 2021 | |
| Janssen Biotech, INC. | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.